| Autor: |
Sener, Ugur, Webb, Mason, Breen, William G., Neth, Bryan J., Laack, Nadia N., Routman, David, Brown, Paul D., Mahajan, Anita, Frechette, Kelsey, Dudek, Arkadiusz Z., Markovic, Svetomir N., Block, Matthew S., McWilliams, Robert R., Dimou, Anastasios, Kottschade, Lisa A., Montane, Heather N., Kizilbash, Sani H., Campian, Jian L. |
| Předmět: |
|
| Zdroj: |
Journal of Immunotherapy & Precision Oncology; Feb2024, Vol. 7 Issue 1, p1-6, 6p |
| Abstrakt: |
Introduction: Proton craniospinal irradiation (pCSI) is a treatment option for leptomeningeal disease (LMD), which permits whole neuroaxis treatment while minimizing toxicity. Despite this, patients inevitably experience progression. Adding systemic therapy to pCSI may improve outcomes. Methods: In this single-institution retrospective case series, we present the feasibility of treatment with pCSI (30Gy, 10 fractions) and an immune checkpoint inhibitor (ICI) in two sequential patients with LMD from melanoma. Results: The first patient developed LMD related to BRAF V600E-mutant melanoma after prior ICI and BRAF-targeted therapy. After pCSI with concurrent nivolumab, the addition of relatlimab, and BRAF-targeted therapy, he remained alive 7 months after LMD diagnosis despite central nervous system progression. The second patient developed LMD related to BRAF-wildtype melanoma after up-front ICI. He received pCSI with concurrent ipilimumab and nivolumab, then nivolumab maintenance. Though therapy was held for ICI hepatitis, the patient remained progression-free 5 months after LMD diagnosis. Conclusion: Adding an ICI to pCSI is feasible for patients with LMD and demonstrates a tolerable toxicity profile. While prospective evaluation is ultimately warranted, pCSI with ICI may confer survival benefits, even after prior ICI. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
